Shionogi Deal With IntraBio Expected to Yield Synergies

Jefferies analysts believe Shionogi's $2 billion acquisition of U.S. rare disease drug developer IntraBio is likely to deliver readily achievable synergies and align with the Japanese drugmaker's growth strategy.